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ABSTRACT
Objectives: Does phacoeECP reduce intraocular
pressure? Is phacoeECP safe?
Design: Retrospective case note review of all patients
undergoing phacoeECP between June 2008 and June
2009. All glaucoma subtypes were included.
Setting: Single District General Hospital
Ophthalmology Department within the UK.
Participants: 58 participants case notes reviewed.
Mean age 79.0 years (SD 69.8).
Interventions: All patients received combined cataract
surgery and endoscopic cyclophotocoagulation.
Outcome measures: Follow-up was 1 day, 1 week, 1,
3, 6, 12, 18 and 24 months for intraocular pressure
(IOP) measurement. Number of medications, visual
acuity and presence of complications were also
assessed.
Results: Of the 58 cases performed, 56 case notes
(97%) were available for analysis. Mean age 79.0 years
(SD 69.8). Mean pre-procedural IOP was
21.54 mm Hg (95% CI 19.86 to 23.22, n¼56). Mean
IOP was 14.43 mm Hg (95% CI 13.65 to 15.21,
n¼53) at 18 months and 14.44 mm Hg (95% CI 13.63
to 15.25, n¼41) at 24 months. The mean drop from
baseline to 18 and 24 months was 7.1 mm Hg.
Statistically signiﬁcant decrease in IOP was
demonstrated at all time points (p<0.001). Mean
medication usage was 1.97 agents (95% CI 1.69 to
2.25) at baseline, 1.96 agents (95% CI 1.70 to 2.22) at
18 months and 2.07 agents (95% CI 1.76 to 2.38) at
24 months. No statistically signiﬁcant change
throughout.
Conclusions: This study conﬁrms the safety of
phacoeECP. In this case series, the IOP-lowering
effect was signiﬁcant at all time points; however, the
effect of cataract surgery alone was not controlled. A
randomised controlled trial is required to draw efﬁcacy
conclusions. The authors proposed endoscopic
cyclophotocoagulation’s main role is to optimise
control of low-risk glaucoma of low-risk patients at the
time of cataract surgery. However, the authors do not
propose that phacoeECP is a substitute for ﬁltration
surgery in high-risk eyes or when low target pressures
(<14 mm Hg) are indicated.
INTRODUCTION
Endoscopic cyclophotocoagulation (ECP) is
an emerging tool in the treatment of glau-
coma. Endoscopic photoablation of ciliary
processes was ﬁrst described by Shields in
1985.
1 2 It was soon apparent that an endo-
scopic approach resulted in more control-
lable and focal tissue effects than transscleral
‘cyclodiode’.
3 Diode laser delivery via the
transscleral route is inefﬁcient, with only 35%
of laser energy reaching its intended target.
The remaining energy causes signiﬁcant
collateral damage to surrounding tissues.
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ARTICLE SUMMARY
Article focus
- Is the safety proﬁle of phacoeECP comparable to
other treatment modalities?
- What is the role of the phacoeECP among other
surgical alternatives?
- What effect does ECP in combination with
phacoemulsiﬁcation have on intraocular
pressure?
Key messages
- PhacoeECP is safe.
- ECP combines synergistically with cataract
surgery.
- PhacoeECP reduces intraocular pressure (IOP)
between baseline (21.54 mm Hg, 95% CI 19.86
to 23.22) and 24 months (14.44 mm Hg, 95% CI
13.63 to 15.25) achieving statistical signiﬁcance
at all time points (p<0.001), but the IOP effect
achieved by the cataract surgery component of
this dual modality treatment is not addressed.
Strengths and limitations of this study
- Data are applicable to typical UK practice and
‘early’/‘moderate’ glaucoma.
- This study suggests that ECP may cause
additional IOP lowering than cataract surgery
alone, but judgement is reserved until a prospec-
tive and controlled study is conducted.
- ECP may have a role outside complex and
refractory glaucoma.
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Open Access ResearchPresumably due to its similar site of action, ECP has been
grouped with transscleral cycloablation and is commonly
perceived to inherit the unfavourable side effect proﬁle
of its anatomical brethren. The American Academy of
Ophthalmology concluded in 2001 that ECP is safer than
transscleral therapy
6 and 10 years later many indications
have been suggested for ECP, refractory glaucoma,
78
paediatric glaucoma,
9e11 aphakic glaucoma
9 and severe
corneal disease.
10 12 All show promise but are only
supported by case reports, opinion articles and small
case series. However, these subtypes have large variability
in disease severity and hence surgical outcomes and
account for a small proportion of the glaucoma work-
load treated by most UK centres.
This paper aims to demonstrate the efﬁcacy and safety
combined ECP and cataract surgery (phacoeECP) to
optimise control of ‘early’ glaucoma for a population
representative of the core glaucoma workload in the UK.
MATERIALS AND METHODS
A retrospective case note audit of all patients under-
going phacoeECP between June 2008 and June 2009.
Patient details were located using theatre records. At
time of decision to treat phacoeECP was offered to
optimise intraocular pressure (IOP) control if concur-
rent ‘early’ glaucoma (MD >  6 decibels, Hodapp
Classiﬁcation) was present at the time of decision to
operate for clinically signiﬁcant cataract. Intraocular
pressures of 12 mm Hg or higher on medical therapy
were considered suitable for ECP with no upper limit.
Previous laser trabeculoplasty or glaucoma surgery
(trabeculectomy, deep sclerectomy) was not a reason for
exclusion. All glaucoma subtypes were included
including pseudoexfoliation, pigment dispersion
syndrome and narrow angle glaucoma. Ocular hyper-
tension was not considered an indication for ECP.
Follow-up
Patient were seen following surgical intervention at
1 day, 1 week, 1, 3, 6, 12, 18 and 24 months. Baseline IOP
was taken as the pressure measured at decision to treat as
this was present for all patients. Mean time between
decision to treat and surgery was 7 weeks (range
3e10 weeks). Pressure was measured using a calibrated
Goldmann tonometer and continuation of each
patient’s normal IOP-lowering agents was checked. The
presence of complications was assessed at each time
point. Observers were not masked to the treatment
performed.
Surgical technique
Cases were performed by three consultant surgeons and
two registrars in one moderate-sized unit (district general
hospital, 700 beds). All patients received surgery with
standardised incisions, viscoelastic and intraocular lens.
ECP was performed post-IOL insertion through the main
incision and the sideport enlarged to 2.75 mm. The
straight endoscopic probe was used (Endo Optiks, Little
Silver, USA) delivering 810 nm diode laser (Iridex
OcuLight SL, Mountain View, California, USA) at
250 mW and 3500 ms settings (total 0.875 watts). All
processes received a single 3.5 s exposure. Treatment
extent was dependent on access. In all cases, all accessible
ciliary processes were photocoagulated hence at least 300
degrees were treated in all cases. Intracameral dexa-
methasone 0.8 mg/0.2 ml (Hospira, Lake Forest, Cali-
fornia, USA) was administered to all patients in addition
to standard cataract antibiotic prophylaxis (intracameral
cefuroxime 1.0 mg/0.1 ml). All patients received stand-
ardised postoperative therapy (g. chloramphenicol four
times a day for 4/52 and g. dexamethasone 0.1% four
times a day for 4 weeks) and instructions to continue
their usual preoperative IOP agents.
Statistical analysis
Data were recorded in an Excel spreadsheet (Microsoft
Ofﬁce 2007; Microsoft Corporation) and then trans-
ferred to GraphPad Prism (V.5.0, GraphPad software).
The data were analysed for IOP and drop use at each
time point. Mean IOP and drop use were calculated
together with their 95% CIs. Multiple comparisons of
IOP at all time points were undertaken using repeated
measures analysis of variance. Bonferroni’s multiple
comparison post-test was undertaken to compare pre-
treatment IOP with IOP at each subsequent time point.
The mean differences in IOP with 95% CIs are given.
Medication use cannot be assumed to follow
a Gaussian distribution. Therefore, drop use was
analysed using Friedman’s test. Using the null hypoth-
esis that no signiﬁcant difference in drop use exists
between time points, Dunn’s multiple comparison test
was undertaken to compare pre-treatment drop use with
drop use at each subsequent time point. p Values <0.05
were considered statistically signiﬁcant throughout.
RESULTS
Of the 58 cases performed between 1 June 2008 and 1
June 2009, 56 case notes (97%) were available for anal-
ysis. Two records (3%) could not be located despite
repeated attempts. The mean age of the 22 men (39%)
and 34 women (61%) was 79.0 years (SD 69.8 years).
Mean follow-up was 22 months (63.2 months) (range
12e24 months). Three patients (5%) had pseudoexfo-
liation, one patient (2%) had pigment dispersion
syndrome and four patients (7%) were narrow-angle
subtype. The remaining 48 patients (86%) were primary
open-angle glaucoma. No normal tension patients were
in the cohort. Previous glaucoma intervention included
two patients (4%) whom had previous argon laser
trabeculoplasty. None had previous ﬁltration surgery.
IOP outcomes
Table 1 documents IOP outcomes over the study time
points and is demonstrated graphically in ﬁgure 1. Mean
pre-procedural IOP was 21.54 mm Hg (95% CI 1.68,
n¼56). A statistically signiﬁcant decrease in IOP
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all time points, beginning at 1 day following treatment.
The mean IOP at 18 and 24 months was 14.43 mm Hg
(95% CI 0.78, n¼53) and 14.44 (95% CI 0.81, n¼41),
respectively. The mean difference in IOP from baseline
to 18 and 24 months was 7.1 mm Hg (p<0.001).
Surgical failure was deﬁned as IOP >21 mm Hg or not
reduced by at least 20% for two consecutive visits from
3 months onwards. A KaplaneMeier survival curve
(ﬁgure 2) plots survival over time. At 24 months, survival
was 76%.
Medication outcomes
The analysis of intraocular pressure-lowering medica-
tions at each time point is shown in table 2 and is
demonstrated graphically in ﬁgure 3. The number
shown represents the number of topical IOP-lowering
agents not the number of bottles used. For example,
ﬁxed prostaglandin and b blocker combinations were
recorded as two medications. Preoperative mean medi-
cation usage was 1.97 agents (95% CI 0.28). At 18 and
24 months, respectively, the mean number of topical
agents was 1.96 (95% CI 0.26) and 2.07 (95% CI 0.31),
with no statistically signiﬁcant change in agent use
compared with pre-treatment. No patients (0%) received
oral or intravenous acetazolamide at any point.
Visual acuity outcomes
No patients (0%) lost best corrected visual acuity at 3, 6,
12, 18 or 24 months compared with baseline.
Complications
Fifty-three cases (95%) had no complication. There was
one case (2%) of steroid-related raised IOP at 1 month
(19 mm Hg at week 1 to 30 mm Hg at month 1), which
returned to baseline upon cessation of steroid. One case
(2%) had vitreous in the anterior chamber noted on the
ﬁrst postoperative day with a peaked pupil. The postu-
lated mechanism was a small area of zonular dehiscence
not noted during surgery. There was no intraocular lens
tilt, IOL decentration or IOP rise. Nd:YAG was applied to
the strand and vision remained at 6/7.5. There were
three cases (5%) of anterior uveitis postoperatively,
deﬁned as anterior chamber cells of two-plus or greater
but no cases of ﬁbrinous uveitis. Visually acuity in these
cases was 6/6 (one case) and 6/9 (two cases). There
were no cases of hyphaema, hypotony, lens instability or
dislocation, cystoid macular oedema, retinal tears or
endophthalmitis.
DISCUSSION
PhacoeECP safety
The safety proﬁle of ECP in the existing literature is
varied and related to the disease subtype it is employed
to treat. It is not relevant to include safety data from
small case series involving complex or refractory
patients. These procedures are certainly subject to a less
favourable side effect proﬁle than ECP when combined
with phaco.
13
The literature assessing the safety of only ECP in
combination with phaco is scarce. One small study
Table 1 Intraocular pressure (IOP) over time
IOP Pre 1 Day 1 Week 1 Month 3 Months 6 Months 12 Months 18 Months 24 Months
Mean (mm Hg) 21.54 16.44 14.61 14.91 14.12 13.98 13.87 14.43 14.44
95% CI 1.68 1.33 1.04 1.25 0.83 0.73 0.81 0.78 0.81
Analysis of variance
p Value versus
pre-treatment*
<0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
n 5 6 5 45 44 44 9 5 5 5 5 5 3 4 1
*Bonferroni’s multiple comparison post-test.
Figure 1 Mean intraocular pressure (IOP) over time with
95% CIs.
Figure 2 KaplaneMeier survival curve. Failure ¼ “intraocular
pressure 21 or <20% drop from baseline.”
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corneal oedema and iris burn without any hypotony,
macular oedema or retinal detachment.
11 No uveitis rate
is reported. The largest series (n¼368) of phacoeECP
reported IOP spikes in 14%, ﬁbrinous uveitis in 7%,
cystoid macular oedema in 4% and transient hypotony in
2%.
13 Interestingly, both of these papers do not cite the
routine use of intracameral dexamethasone to suppress
postoperative inﬂammation. Intracameral dexametha-
sone has been shown to produce a statistically signiﬁcant
decrease in aqueous inﬂammatory cells 1 day after cata-
ract surgery when compared with controls.
14 There were
no adverse effects from instillation of the drug, and IOP
on day 1 was statistically similar to control
14 hence why
intracameral dexamethasone was routinely used for
phacoeECP.
PhacoeECP efﬁcacy
Our data illustrate signiﬁcant decrease in IOP, which is
sustained from day 1 until at least 24 months. No statis-
tically or clinically signiﬁcant changes in the number
intraocular pressure-lowering topical agents were found
to explain these decreases.
Again, the majority of evidence in ophthalmic litera-
ture suggests ECP is efﬁcacious in small case series or in
small trials but emphasis is for highly speciﬁc compli-
cated or refractory indications.
7e12 15 16 There are only
three papers reporting outcomes from ECP combined
with phaco. A paper on 40 eyes with 6-month follow-up
documents encouraging IOP reduction.
17 Statistically
signiﬁcant IOP reduction for combined phaco and ECP
was achieved when 180 degrees (23.6 mm Hg (95% CI
3.89) to 16.0 mm Hg (95% CI 2.77)) or 360 degrees
(24.5 mm Hg (95% CI 8.99) to 13.00 mm Hg (95% CI
3.09)) were cyclophotocoagulated. Both groups also
required statistically fewer drops at 6 months than at
baseline (180 degrees ¼2.47 to 1.93 drops, 360
degrees¼2.56 to 0.52 drops).
17
Long-term data have only emerged in the last 2 years.
Twenty-four-month data from a cohort of 29 eyes showed
a statistically signiﬁcant IOP effect at 18 months
(21.8 mm Hg (95% CI 6.6) to 16.2 mm Hg (95% CI 4.1,
p¼0.02)) on statistically less drops (2.0 (95% CI 1.0) to
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Figure 3 Medications over time.
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’PhacoeECP’: combined endoscopic cyclophotocoagulation and cataract surgery0.9 (95% CI 0.9, p¼0.04)). However, statistical signiﬁ-
cance was not reached at 24 months (17.9 mm Hg (95%
CI 4.9) on 1.2 (95% CI 0.8) drops, p¼0.18). Notably, this
cohort contained a mixed bag of subtypes including
PXF, normal tension and narrow angle glaucoma.
11
Most recently, a Brazilian paper documents results
from 368 eyes with follow-up exceeding 2 years.
13 Statis-
tical signiﬁcance (p#0.001) was reported at all time
points comparing IOP at baseline (23.1 mm Hg, 95% CI
5.6) to 12 months (12.2 mm Hg, 95% CI 2.19),
24 months (12.14 mm Hg, 95% CI 2.9) and last
appointment (12.3 mm Hg, 95% CI 2.44, mean follow-
up 35.2 months SD 8.1).
13 Furthermore, there was
a statistically signiﬁcant reduction in medication from
1.44 (95% CI 0.97) drops preoperatively to 0.37 (95% CI
0.68) at 2 years (p#0.001 for all time points). IOP
reductions of the magnitude seen from this report
13
were not reproduced in our series presumably due to the
differences in pigmentationdBrazilian eyes are more
pigmented, absorb more laser energy and hence should
illustrate a greater IOP drop side effects in our series
were less common, which may again be explained by
differences in laser energy uptake.
The IOP effect of cataract surgery alone? A difﬁcult question
It is well documented that cataract surgery confers
a pressure reduction in eyes with or without
glaucoma.
15 16 18 However, this beneﬁt is variable and
dependent on starting IOP and type of glaucoma. For
example, in narrow angle glaucoma, cataract extraction
alone has been shown to normalise IOP
19 and this effect
can be attributed anatomically to the removal of a large
and anteriorly positioned lens and therefore removal of
outﬂow resistance. These eyes also have higher starting
pressures so some of the perceived effect could be due to
regression towards the mean.
18 The effect of lens removal
in open-angle glaucoma is less clear and the exact
mechanism is yet to be elucidated.
16 By deﬁnition, in
open-angle glaucoma, the trabecular meshwork is
unobstructed and most studies suggest a drop in IOP
after cataract surgery is only transient. Reported IOP
changes ranges from a reduction of 8.5 mm Hg in eyes
with a high starting pressure (24e29 mm Hg) to
a 1.7 mm Hg rise in IOP in low-pressure eyes
(14 mm Hg or less).
20 Duration of effect is also
contentious. Effects lasting 12, 18 or 24 months are
commonly reported,
16 18 but continued response is rare.
Meta-analysis in 2002 revealed a 2e4 mm Hg pressure
drop from cataract surgery with effect diminishing after
18e24 months,
21 but more recent papers with longer
follow-up illustrated a drop in IOP of approximately
3 mm Hg with 75%e85% of patients maintaining this
IOP reduction at 5 years.
20 22e25 Many criticisms are
levelled at the attribution of cause and effect within
these papers.
18 A 2011 review of the current evidence
concludes: “the mild and variable nature of any IOP decrease
from lens extraction suggests a marginal beneﬁt only in milder
forms of POAG. There is currently no evidence of any quality to
suggest that lens extraction routinely represents a clinically
useful treatment for primary open angle glaucoma.”
16
The symbiotic combination of cataract surgery and ECP
ECP combines almost symbiotically with cataract surgery.
Glaucoma like cataract is predominantly a disease of the
older population and is often concurrent. Early ECP
necessitated a pars plana approach with its associated
and additional posterior pole risks
1 but can now be
performed through standard phaco incisions. Anatom-
ical access to the ciliary processes is improved by lens
removal, and the instrumentation and viscoelastics
required are inherent to both procedures. The proce-
dure adds 5 min to the on-table time. One of the much
stated risks of ECP over transscleral or trabecular laser
therapydthe need to enter the eye and thus impose
possible infectious complicationsdis also a moot point
with combined surgery.
Limitations of the study
This study represents a retrospective analysis of intraoc-
ular pressure, complication and medication outcomes.
The data are therefore less robust than prospective
collection, but common limitations for retrospective
data of bias and confounding were minimised as all
patients receiving surgery within the 12-month sampling
period were included and only two of 58 case notes were
not available. Visual ﬁeld analysis was also not included.
Any change in ﬁeld parameters is inextricably linked
with lens-related factors in addition to any possible
glaucomatous change and very difﬁcult to separate.
The pressure-lowering effect of the ECP component of
phacoeECP is difﬁcult to isolate. Cataract surgery alone
lowers IOP but the degree of response is multifactorial
(angle depth, starting IOP) and duration rarely persists
beyond 12e24 months. A prospective trial comparing
phacoeECP with phaco-only controls is required to truly
answer the question. The IOP effect of phacoeECP in
this study is greater than most published studies
assessing phaco alone, but direct comparison is neither
wise nor possible.
CONCLUSIONS
The combination of ECP with phacoemulsiﬁcation
shows promise when applied a wide patient population
of mixed-subtype early glaucoma. We, however, do not
propose that phacoeECP is a substitute for ﬁltration
surgery in high-risk eyes, rapidly progressive patients or
when a low target pressure (<14 mm Hg) is indicated.
The results of this study show transposable and safe
results from ECP that can be applied to current UK
glaucoma practice but do not entangle the pressure-
lowering effect of cataract surgery alone. Until a rando-
mised controlled trial compares phaco alone and
phacoeECP, its role outside complex refractory glau-
coma is anecdotal but shows promise.
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